Kymera's fundamental outlook hinges on its ability to convert collaboration milestones into sustainable revenue while managing a heavy R&D burn that reached $119.5M in 2026Q2. The company's asset-light model and strong liquidity (current ratio 9.83) provide ne...
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue growth is erratic, with a 22-fold jump to $65.0M in 2026Q2 from $2.9M in 2025Q4, yet operating losses widened to -$75.6M as R&D expenses consumed 85% of total costs, reflecting a negative operating margin of -116.3%.
Kymera Therapeutics is focused on developing innovative protein degradation treatments for difficult-to-treat diseases, positioning it as a leader in this cutting-edge biopharmaceutical field.
The company has reported positive top-line data from its Phase 1b trial of KT-621 for atopic dermatitis and is advancing to Phase 2b studies, marking progress in its STAT6 degrader program.
The appointment of Dr. Neil Graham as Chief Development Officer brings seasoned drug development expertise to Kymera, potentially accelerating pipeline progress.
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 5, 2026 | -$0.62+13.0% vs -$0.71 | $65M+98.3% vs $33M |
Q2 2026 Apr 30, 2026 | -$0.71+20.2% vs -$0.89 | $34M+315.7% vs $8M |
Q1 2026 Feb 26, 2026 | -$0.97-23.8% vs -$0.78 | $3M-80.9% vs $15M |
Q4 2025 Nov 4, 2025 | -$0.90-26.8% vs -$0.71 | $3M-80.9% vs $14M |
Kymera Therapeutics, Inc. (KYMR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Kymera Therapeutics, Inc. (KYMR) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Kymera Therapeutics (KYMR) reported earnings 30 days ago. What's next for the stock?
KYMR advances KT-621 in atopic dermatitis and asthma, with earlier-than-expected AD data and potential phase III plans by mid-2027.
Benchmark KYMR against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Kymera Therapeutics, Inc. (KYMR)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $115.47 | $9.5B | -31.29 | -16.72% | -794.39% | -25.79% | — | |
| $7.83 | $505.2M | -6.12 | -0.3% | 2.94% | 1.91% | — | |
| $282.12 | $7.87B | -20.93 | -100% | — | -34.15% | — | |
| $41.65 | $4.86B | -13.06 | — | — | -94.56% | — | |
| $24.37 | $2.51B | -30.09 | 120.01% | -54.75% | -7.7% | — | |
| $34.54 | $7.13B | -12.47 | — | -7585.86% | -69.59% | — |
Kymera Therapeutics, Inc. (KYMR) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Kymera Therapeutics, Inc. (KYMR) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 5, 2026·SEC
Jul 27, 2026·SEC
Jun 25, 2026·SEC
Get notified when KYMR posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Kymera Therapeutics, Inc. (KYMR) stock FAQ — growth, dividends, profitability & financials explained
Kymera Therapeutics, Inc. (KYMR) reported $105.0M in revenue for fiscal year 2025.
Kymera Therapeutics, Inc. (KYMR) saw revenue decline by 16.7% over the past year.
Kymera Therapeutics, Inc. (KYMR) reported a net loss of $299.6M for fiscal year 2025.
Kymera Therapeutics, Inc. (KYMR) has a return on equity (ROE) of -25.8%. Negative ROE indicates the company is unprofitable.
Kymera Therapeutics, Inc. (KYMR) had negative free cash flow of $238.0M in fiscal year 2025, likely due to heavy capital investments.
